JP2002542248A5 - - Google Patents

Download PDF

Info

Publication number
JP2002542248A5
JP2002542248A5 JP2000612301A JP2000612301A JP2002542248A5 JP 2002542248 A5 JP2002542248 A5 JP 2002542248A5 JP 2000612301 A JP2000612301 A JP 2000612301A JP 2000612301 A JP2000612301 A JP 2000612301A JP 2002542248 A5 JP2002542248 A5 JP 2002542248A5
Authority
JP
Japan
Prior art keywords
pharmaceuticals
prevention
treatment
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000612301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002542248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2000/003388 external-priority patent/WO2000063211A1/en
Publication of JP2002542248A publication Critical patent/JP2002542248A/ja
Publication of JP2002542248A5 publication Critical patent/JP2002542248A5/ja
Withdrawn legal-status Critical Current

Links

JP2000612301A 1999-04-17 2000-04-14 ハロアルコキシイミダゾナフチリジン Withdrawn JP2002542248A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99107688.6 1999-04-17
EP99107688 1999-04-17
PCT/EP2000/003388 WO2000063211A1 (en) 1999-04-17 2000-04-14 Haloalkoxy imidazonaphthyridines

Publications (2)

Publication Number Publication Date
JP2002542248A JP2002542248A (ja) 2002-12-10
JP2002542248A5 true JP2002542248A5 (https=) 2007-05-10

Family

ID=8237986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000612301A Withdrawn JP2002542248A (ja) 1999-04-17 2000-04-14 ハロアルコキシイミダゾナフチリジン

Country Status (12)

Country Link
US (1) US6503923B1 (https=)
EP (1) EP1173439B1 (https=)
JP (1) JP2002542248A (https=)
AT (1) ATE240956T1 (https=)
AU (1) AU3966600A (https=)
CA (1) CA2370231A1 (https=)
DE (1) DE60002855T2 (https=)
DK (1) DK1173439T3 (https=)
ES (1) ES2199810T3 (https=)
PT (1) PT1173439E (https=)
SI (1) SI1173439T1 (https=)
WO (1) WO2000063211A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008151B1 (ru) * 2000-10-25 2007-04-27 Алтана Фарма Аг Полизамещенные имидазопиридины в качестве ингибиторов желудочной секреции
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MXPA03007888A (es) * 2001-03-08 2003-12-04 Astrazeneca Ab Compuestos para tratamiento y prevencion de ulcera gastrica inducida por medicamentos.
HUP0400379A3 (en) 2001-08-02 2007-10-29 Altana Pharma Ag Tricyclic epoxides and their use for the preparation of pharmaceutically active agents
PL368586A1 (en) * 2001-08-03 2005-04-04 Altana Pharma Ag Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders
US20040235882A1 (en) * 2001-08-03 2004-11-25 Jorg Senn-Bilfinger Amino-substituted imidazopyridines for the treatment of gastrointestial diseases
US7314935B2 (en) 2002-02-15 2008-01-01 Altana Pharma Ag Tricyclic n-acyl compounds
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AU2003288071A1 (en) 2002-11-19 2004-06-15 Altana Pharma Ag 8-substituted imidazopyridines
MXPA05008490A (es) * 2003-02-17 2005-10-18 Altana Pharma Ag Combinaciones que contienen imidazopiridinas y su uso en el tratamiento de enfermedades gastrointestinales inflamatorias.
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
WO2004105795A1 (en) * 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
KR20060099524A (ko) 2003-11-03 2006-09-19 아스트라제네카 아베 무증상 위식도 역류의 치료를 위한 이미다조[1,2-a]피리딘유도체
AR046893A1 (es) * 2003-12-16 2005-12-28 Altana Pharma Ag Bencimidazoles triciclicos
WO2005058894A1 (en) 2003-12-19 2005-06-30 Altana Pharma Ag Intermediates for the preparation of tricyclic dihydropyrano -imidazo -pyridines derivatives
NZ549011A (en) * 2004-02-17 2009-04-30 Altana Pharma Ag Tricyclic imidazopyridines and intermediates for the synthesis thereof
US7931659B2 (en) * 2004-09-10 2011-04-26 Penumbra, Inc. System and method for treating ischemic stroke
CA2582256A1 (en) * 2004-10-01 2006-04-13 Altana Pharma Ag Substituted tricyclic benzimidazoles
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468400A (en) 1982-12-20 1984-08-28 Schering Corporation Antiulcer tricyclic imidazo [1,2-a]pyridines
IL108520A (en) * 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0971922B1 (en) * 1997-03-24 2004-04-28 ALTANA Pharma AG Tetrahydropyrido compounds
US6436953B1 (en) 1998-09-23 2002-08-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyridoethers

Similar Documents

Publication Publication Date Title
JP2002542248A5 (https=)
USD449939S1 (en) Bed
USD470329S1 (en) Bed
NO2020019I1 (no) Maraviroc eventuelt i form av et farmasøytisk akseptabelt salt
USD471628S1 (en) Medical vial
NO2020007I1 (no) Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
JP2003503454A5 (https=)
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
NO2012009I1 (no) Kombinasjonsprodukt av saxaglipin og metformin og farmasøytisk akseptable salter frav, herunder HCI saltene av saxaglipin og metformin
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
NO2013004I2 (no) Axitinib, valgfritt i form av et farmasøytisk aksentabelt salt
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
HRP20010632A2 (en) Matrix tablet enabling prolonged release of gliclazide after administration by the oral route
JP2005507892A5 (https=)
JP2003526626A5 (https=)
IL152479A0 (en) Pharmaceutical form of administration for peptides, methods for its production and use
WO2006004449A3 (en) A combination composition
HRP20050371A2 (en) Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
JP2005509503A5 (https=)
JP2001513504A5 (https=)
DK1225902T3 (da) Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden
USD657863S1 (en) Mask
USD529741S1 (en) Towel ring
PT1131297E (pt) Certas caprolactamas substituidas composicoes farmaceuticas contendo-as e sua utilizacao no tratamento de tumores